Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Purchased by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 61.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 377,031 shares of the company's stock after buying an additional 143,506 shares during the period. Greenwood Capital Associates LLC's holdings in Teva Pharmaceutical Industries were worth $5,795,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Oarsman Capital Inc. acquired a new position in Teva Pharmaceutical Industries during the fourth quarter worth $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $44,000. IFP Advisors Inc lifted its stake in shares of Teva Pharmaceutical Industries by 96.1% in the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company's stock valued at $88,000 after purchasing an additional 1,960 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.7% in the 4th quarter. Quadrant Capital Group LLC now owns 4,377 shares of the company's stock valued at $96,000 after purchasing an additional 949 shares during the last quarter. Finally, Capital Analysts LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $102,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Bank of America upped their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and upped their price target for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They issued a "buy" rating and a $25.00 price target on the stock. Finally, The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $24.44.

Teva Pharmaceutical Industries Stock Up 2.0%

TEVA stock traded up $0.35 during mid-day trading on Thursday, reaching $17.67. The company had a trading volume of 8,361,247 shares, compared to its average volume of 10,177,718. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The company has a market capitalization of $20.27 billion, a price-to-earnings ratio of -12.19, a price-to-earnings-growth ratio of 1.44 and a beta of 0.60. The firm has a fifty day simple moving average of $15.97 and a 200 day simple moving average of $17.41. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. The company had revenue of $3.89 billion for the quarter, compared to analyst estimates of $3.99 billion. During the same quarter last year, the company earned $0.48 EPS. Teva Pharmaceutical Industries's revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the sale, the executive vice president now directly owns 9,989 shares of the company's stock, valued at $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.49% of the company's stock.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.